All In Biotech

Drug Trial Radar · NCT07876128

A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002)

A Phase 1b/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of MK-2750 in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Nov 16, 2026

Primary completion

Apr 12, 2029

Study completion May 30, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MK-2750 is a trial medicine designed to treat certain solid tumors. MK-2750 is a type of treatment called an antibody drug conjugate (ADC). ADCs attach to a protein on cancer cells and deliver medicine to destroy those cells. The goals of this trial are to learn: * About the safety of MK-2750 and if participants tolerate it. Tolerate means participants will receive trial treatment in the trial unless they need to stop it due to health problems. * How many participants have cancer respond (get smaller or go away) to MK-2750

Conditions

  • Advanced Solid Tumors
  • Malignant Neoplasm

Interventions

  • MK-2750Biological

    Administered as an intravenous (IV) infusion

  • 5-HT3 serotonin receptor antagonistDrug

    Administered as a premedication per the approved product label

  • NK-1 receptor antagonistDrug

    Administered as a premedication per the approved product label

  • CorticosteroidDrug

    Administered as a premedication per the approved product label

  • Steroid mouthwash (dexamethasone or equivalent)Drug

    Administered orally per the approved product label as a rescue medication

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 2 years
  2. Number of Participants Who Discontinued Study Intervention Due to an AETime frame: Up to approximately 2 years
  3. Objective Response Rate (ORR)Time frame: Up to approximately 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.